LuSeed Vascular Appoints Robert Stern to its Board of Directors

LuSeed Vascular, the developer of an innovative solution for the treatment of brain aneurysms, has announced that Robert Stern, an experienced medical device executive and investor, has been nominated as Vice Chairman of the Board of Directors.

Mr. Robert Stern currently serves as an advisor to several medical device companies and has been a board member of multiple neurovascular-focused companies, including Flexible Stenting Solutions, Reverse Medical, and Neuravi – all of which have been sold to strategic investors.

Mr. Stern is currently the vice chairman of MIVI Neurosciences, an Eden Prairie, Minnesota company, and serves in various philanthropic boards.

Mr. Nitzan Hirsh and Mr. Amir Arthur, co-founders of LuSeed Vascular, say that “We are honored and thrilled to have Robert Stern as part of our Board as we are moving ahead towards strategic steps. We are confident that Mr. Stern’s extensive background in the world of medical entrepreneurship and M&A, and especially in the intervascular field, will be an asset in leading the company to its business and clinical goals, providing a life-saving solution for the treatment of cerebral aneurysm, and improving the patients’ rehabilitation process.”

Mr. Robert Stern says: “I am proud to join LuSeed Vascular’s Board and take part in its journey in developing the first intrasaccular flow diverter that can treat sidewall as well as bifurcating aneurysms, while also being potentially suitable for ruptured and non-ruptured cases. I believe that as a team, we have a unique opportunity to provide a superior solution for the treatment of brain aneurysms, one that can be beneficial to the patients as well as to all the stakeholders.”

The device developed by LuSeed is a revolutionary implant that is suitable for the vast majority of aneurysms. This implant is simple and easy to use, as the interventionalist can access the aneurysm from different angles without compromising device stability, making it highly suitable for sidewall and eccentric cases. LuSeed’s device is the first if its category that does not have a marker which protrudes into the parent artery, drastically reducing the potential need for long term dual antiplatelet. The Luseed device has a specifically high mesh density which is intended to promote a safe an efficient occlusion of ruptured cases.

LuSeed Vascular was co-founded in 2018 by Nitzan Hirsh and Amir Arthur, experienced entrepreneurs in the medical device field, funded Sanara Ventures, private investors as well as a grants from the Israel Innovation Authority.

The market for interventional treatment of cerebral aneurysms is characterized by rapid global growth and is expected to grow from a volume of $1.6 billion in 2022 to $3.15 billion in 2027.

The company headquarters and R&D are located in Israel.

Hot this week

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."